Relapse rate of 53% vs. 31% (p=0.007) among 136 CLL pts who did or did not receive alemtuzumab within 12 months prior to nonmyeloablative HCT. Adjustment for pre-transplant risk factors did not change the significant difference in relapse rate between the two groups.